Hideki Ikeda

Department Of Otorhinolaryngology/Head & Neck Surgery
Chiba, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

A truncated TNS3 isoform expressed in metastatic triple negative breast cancer stabilizes FAK and promotes lung metastasis.

A truncated TNS3 isoform expressed in metastatic triple negative breast cancer stabilizes FAK and promotes lung metastasis.

Journal: Oncogene

Published: December 21, 2025

Author Correction: Immune evasion through mitochondrial transfer in the tumour microenvironment.

Author Correction: Immune evasion through mitochondrial transfer in the tumour microenvironment.

Journal: Nature

Published: July 27, 2025

Mitochondrial transfer at the crossroads of cancer, stromal, and immune cells.

Mitochondrial transfer at the crossroads of cancer, stromal, and immune cells.

Journal: Trends in cell biology

Published: July 10, 2025

Pan-cancer analysis of RNA expression signatures associated with cancer tissue architecture.

Pan-cancer analysis of RNA expression signatures associated with cancer tissue architecture.

Journal: British journal of cancer

Published: March 23, 2025

Publisher Correction: Immune evasion through mitochondrial transfer in the tumour microenvironment.

Publisher Correction: Immune evasion through mitochondrial transfer in the tumour microenvironment.

Journal: Nature

Published: February 13, 2025

Investigation of cardiotoxicity in patients treated with osimertinib: findings from the OSI-FACT study.

Investigation of cardiotoxicity in patients treated with osimertinib: findings from the OSI-FACT study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: January 21, 2025

Osimertinib as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in a Real-World Setting: Updated Overall Survival Data (OSI-FACT-OS).

Osimertinib as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in a Real-World Setting: Updated Overall Survival Data (OSI-FACT-OS).

Journal: Clinical lung cancer

Published: January 01, 2025

Somatic mutations in tumor-infiltrating lymphocytes impact on antitumor immunity.

Somatic mutations in tumor-infiltrating lymphocytes impact on antitumor immunity.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: August 21, 2024

Corrigendum to "Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)" [Lung Cancer 186 (2023) 107426].

Corrigendum to "Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)" [Lung Cancer 186 (2023) 107426].

Journal: Lung cancer (Amsterdam, Netherlands)

Published: December 30, 2023

Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP).

Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP).

Journal: Lung cancer (Amsterdam, Netherlands)

Published: September 09, 2023

Immunologic Significance of CD80/CD86 or Major Histocompatibility Complex-II Expression in Thymic Epithelial Tumors.

Immunologic Significance of CD80/CD86 or Major Histocompatibility Complex-II Expression in Thymic Epithelial Tumors.

Journal: JTO clinical and research reports

Published: May 27, 2023

Venous Stent Placement for Malignant Vena Cava Syndrome in a Patient with Liposarcoma.

Venous Stent Placement for Malignant Vena Cava Syndrome in a Patient with Liposarcoma.

Journal: The American journal of case reports

Published: January 11, 2023

Showing 1-12 of 21

Last Updated: 09/26/2026